Impairment of T Cell Immunity by the Respiratory Syncytial Virus: Targeting Virulence Mechanisms for Therapy and Prophylaxis

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|16|34|4609-4625

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.16, Iss.34, 2009-12, pp. : 4609-4625

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis: A Critical and Systematic Review

By PrescottJr William A. Doloresco Fred Brown Jack Paladino Joseph A.

PharmacoEconomics, Vol. 28, Iss. 4, 2010-04 ,pp. : 279-293

Adis International

Access to resources Recommend Favorite

Palivizumab: A Review of its Use as Prophylaxis for Serious Respiratory Syncytial Virus Infection

By Fenton Caroline Scott Lesley J. Plosker Greg L.

Pediatric Drugs, Vol. 6, Iss. 3, 2004-01 ,pp. : 177-197

Adis International

Access to resources Recommend Favorite

Overcoming T-cell-mediated immunopathology to achieve safe respiratory syncytial virus vaccination

By Castilow Elaine M Varga Steven M

Future Virology, Vol. 3, Iss. 5, 2008-09 ,pp. : 445-454

Future Medicine

Access to resources Recommend Favorite

Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis

By Nuijten Mark J.C. Wittenberg Wolfgang Lebmeier Maximilian

PharmacoEconomics, Vol. 25, Iss. 1, 2007-01 ,pp. : 55-71

Adis International

Access to resources Recommend Favorite

Respiratory syncytial virus antiviral agents

By Prince G.A.

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 6, 1999-06 ,pp. : 753-762

Informa Healthcare

Access to resources Recommend Favorite